Carsten Nieder1, Bård Mannsåker2, Astrid Dalhaug3, Adam Pawinski2, Ellinor Haukland2. 1. Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway carsten.nieder@nlsh.no. 2. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway. 3. Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway.
Abstract
BACKGROUND/AIM: Connections exist between inflammation and cancer, for example with regard to disease progression and prognosis. Therefore, we investigated whether systemic inflammatory processes indicated by increased serum C-reactive protein (CRP) provide prognostic information for physicians prescribing palliative radiotherapy. PATIENTS AND METHODS: We analyzed data from 781 patients and evaluated prognostic factors for survival. RESULTS: Only 277 patients (35%) had CRP <8 mg/l before radiotherapy. No significant association was observed between CRP level and steroid treatment. In patients with the highest CRP level (>60 mg/l, 20% of patients), intravenous therapy with antibiotics was more common. CRP significantly influenced survival and contributed prognostic information together with established parameters, such as performance status (PS). In the multivariate model, white blood cell count did not provide relevant additional information. A simple four-tiered prognostic score solely based on CRP showed promising results. CONCLUSION: Most patients treated with palliative radiotherapy had increased CRP. This widely available biomarker might improve decision-making and should be further validated.
BACKGROUND/AIM: Connections exist between inflammation and cancer, for example with regard to disease progression and prognosis. Therefore, we investigated whether systemic inflammatory processes indicated by increased serum C-reactive protein (CRP) provide prognostic information for physicians prescribing palliative radiotherapy. PATIENTS AND METHODS: We analyzed data from 781 patients and evaluated prognostic factors for survival. RESULTS: Only 277 patients (35%) had CRP <8 mg/l before radiotherapy. No significant association was observed between CRP level and steroid treatment. In patients with the highest CRP level (>60 mg/l, 20% of patients), intravenous therapy with antibiotics was more common. CRP significantly influenced survival and contributed prognostic information together with established parameters, such as performance status (PS). In the multivariate model, white blood cell count did not provide relevant additional information. A simple four-tiered prognostic score solely based on CRP showed promising results. CONCLUSION: Most patients treated with palliative radiotherapy had increased CRP. This widely available biomarker might improve decision-making and should be further validated.
Authors: Ragnhild Habberstad; Trude Camilla Salvesen Frøseth; Nina Aass; Tatiana Abramova; Theo Baas; Siri Tessem Mørkeset; Augusto Caraceni; Barry Laird; Jason W Boland; Romina Rossi; Elena Garcia-Alonso; Hanne Stensheim; Jon Håvard Loge; Marianne Jensen Hjermstad; Ellen Bjerkeset; Asta Bye; Jo-Åsmund Lund; Tora Skeidsvoll Solheim; Ola Magne Vagnildhaug; Cinzia Brunelli; Jan Kristian Damås; Tom Eirik Mollnes; Stein Kaasa; Pål Klepstad Journal: BMC Palliat Care Date: 2018-09-28 Impact factor: 3.234